Inogen (NASDAQ:INGN) Releases Earnings Results

Inogen (NASDAQ:INGNGet Rating) released its quarterly earnings results on Thursday. The medical technology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.15), MarketWatch Earnings reports. The firm had revenue of $80.39 million for the quarter, compared to the consensus estimate of $76.56 million. Inogen had a negative return on equity of 1.70% and a negative net margin of 1.77%. The firm’s revenue was down 7.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.03) EPS.

INGN traded up $0.85 on Friday, reaching $24.94. The company had a trading volume of 383,237 shares, compared to its average volume of 166,329. The company has a fifty day moving average of $30.54 and a 200-day moving average of $32.00. The company has a market capitalization of $569.63 million, a P/E ratio of -28.34 and a beta of 1.01. Inogen has a one year low of $23.04 and a one year high of $82.35.

INGN has been the subject of several recent research reports. StockNews.com initiated coverage on shares of Inogen in a research report on Thursday, March 31st. They set a “hold” rating for the company. TheStreet lowered shares of Inogen from a “c-” rating to a “d” rating in a research report on Friday, March 11th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $43.50.

In related news, Director Ray Benjamin M. Anderson sold 4,516 shares of the stock in a transaction dated Thursday, March 3rd. The shares were sold at an average price of $34.68, for a total value of $156,614.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.29% of the company’s stock.

Several large investors have recently bought and sold shares of INGN. Royal Bank of Canada boosted its position in shares of Inogen by 17.8% during the 3rd quarter. Royal Bank of Canada now owns 4,126 shares of the medical technology company’s stock valued at $177,000 after purchasing an additional 622 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Inogen by 6.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 171,634 shares of the medical technology company’s stock valued at $7,397,000 after purchasing an additional 10,534 shares in the last quarter. Citigroup Inc. boosted its position in shares of Inogen by 50.8% during the 4th quarter. Citigroup Inc. now owns 21,396 shares of the medical technology company’s stock valued at $727,000 after purchasing an additional 7,205 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Inogen by 4.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 144,555 shares of the medical technology company’s stock valued at $4,915,000 after purchasing an additional 6,129 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Inogen by 20.8% during the 4th quarter. Geode Capital Management LLC now owns 348,619 shares of the medical technology company’s stock valued at $11,853,000 after purchasing an additional 60,010 shares in the last quarter. Institutional investors own 96.01% of the company’s stock.

Inogen Company Profile (Get Rating)

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Articles

Earnings History for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.